Skip to Content
  • MyChart

    Log in to our secure, personalized website to manage your care (formerly myMDAnderson).

  • Request an Appointment

    If you are ready to make an appointment, select a button on the right. If you have questions about UT MD Anderson’s appointment process, our information page may be the best place to start.

    Appointment Information
    New Patients Current Patients Referring Physicians
  • Every Breakthrough
    Begins With You

    Gifts to UT MD Anderson’s historic philanthropic campaign help accelerate discovery, transform lives and bring hope to more patients than ever before.

    Learn more about Only Possible Here
    Donate Today only-possible-here-logo
The University of Texas MD Anderson Cancer Center
  • Clinical Trials
  • Locations
  • Careers
  • Contact Us
  • Our Doctors
    • Español
    • عربى
    • 中文
    • Türkçe
Clear
close
      MyChart
      Donate Today
      • Clinical Trials
      • Locations
      • Careers
      • Contact Us
        • Español
        • عربى
        • 中文
        • Türkçe
      • Request an Appointment
      • New Patients
      • Current Patients
      • Referring Physicians
      • Patients & Family
          • Becoming Our Patient Home
          • Why UT MD Anderson
          • Planning for Care
          • Getting to UT MD Anderson
          • While You're Here
          • International Center
          • Services and Amenities
          • Insurance & Billing
          • Second Opinion Appointments
          • Diagnosis & Treatment Home
          • Cancer Types
          • A New Diagnosis
          • Treatment Options
          • Care Centers & Clinics
          • Emotional & Physical Effects
          • Patient Support
          • Clinical Trials
          • Supporting a Loved One Home
          • Caregiver Roles & Challenges
          • Children and Teens
          • Taking Care of Yourself
          • Helping a UT MD Anderson Patient
          • Dealing with Loss
          • Life After Cancer Home
          • Follow-up Care After Cancer Treatment
          • Long-Term Effects of Cancer
          • Social & Emotional Impacts of Cancer
          • Legal & Financial Impacts of Cancer
          • Survivorship Week
        • Request an Appointment Current Patients

          Find information and resources for current and returning patients.

          Clinical Trials

          Learn about clinical trials at UT MD Anderson and search our database for open studies.

      • Prevention & Screening
          • Manage Your Risk Home
          • Tobacco Control
          • Diet
          • Body Weight
          • Physical Activity
          • Skin Safety
          • HPV
          • Hepatitis
          • Alcohol
          • Family History Home
          • Genetic Testing
          • Hereditary Cancer Syndromes
          • Genetic Counseling and Testing FAQs
          • Cancer Screenings Home
          • Mammograms & Breast Cancer Screening
          • Cervical Cancer Screening
          • Colorectal Cancer Screening
          • Endometrial Cancer Screening
          • Liver Cancer Screening
          • Lung Cancer Screening
          • Mobile Mammography
          • Ovarian Cancer Screening
          • Prostate Cancer Screening
          • Skin Cancer Screening
          • Women's Cancer Screening
          • Men's Cancer Screening
        • Cancer Prevention Center 

          The Lyda Hill Cancer Prevention Center provides cancer risk assessment, screening and diagnostic services.

      • Donors & Volunteers
          • Donate Home
          • Raise Money
          • Honor Loved Ones
          • Create Your Legacy
          • Endowments
          • Caring Fund
          • Matching Gifts
          • Foundation and Corporation Relations
          • Volunteer Home
          • Why Volunteer
          • On-Site Volunteers
          • Volunteer Endowment
          • Patient Experience
          • Teen Volunteer Leadership Program
          • Children's Cancer Hospital Councils
          • Other Ways to Help Home
          • Give Blood
          • Shop UT MD Anderson
          • Children's Art Project
          • Donate Goods or Services
          • Attend Events
          • Cord Blood Bank
          • Corporate Alliances Home
          • Current Alliances
        • Join the Campaign to End Cancer 

          Help us celebrate and fuel the groundbreaking innovations and transformative advancements that define UT MD Anderson.

      • For Physicians
          • Refer a Patient Home
          • Health Care Provider Resource Center
          • Referring Provider Team
          • Insurance Information
          • International Referrals
          • myMDAnderson for Physicians
          • Second Opinion Pathology
          • Clinical Trials Home
          • Clinical Tools & Resources Home
          • Clinical Calculators
          • Clinical Practice Algorithms
        • myMDAnderson for Physicians 

          Our personalized portal helps you refer your patients and communicate with their UT MD Anderson care team.

      • Research
          • Departments, Labs and Institutes Home
          • Departments and Divisions
          • Labs
          • Research Centers and Programs
          • Institutes
          • Specialized Programs of Research Excellence (SPORE) Grants
          • Research Areas Home
          • Basic Science
          • Translational Research
          • Clinical Research
          • Prevention & Personalized Risk Assessment
          • Research Resources Home
          • Excellence in Science
          • Core Facilities and Services
          • Conferences & Seminars
          • Why Research at UT MD Anderson
          • STRIDE
          • NCI-Designated Cancer Center
          • Data Resources
        • Clinical Trials 

          As part of our mission to eliminate cancer, UT MD Anderson researchers conduct hundreds of clinical trials to test new treatments for both common and rare cancers.

      • Education & Training
          • Degree-Granting Schools Home
          • School of Health Professions
          • MD Anderson UTHealth Houston Graduate School
          • Research Training Home
          • Early Career Pathway Programs
          • Predoctoral Training
          • Postdoctoral Training
          • Mentored Faculty Programs
          • Career Development
          • Clinical Training Home
          • Graduate Medical Education
          • Clinical Education for Non-Physicians
          • Nursing Education & Training
          • Continuing Education & Review Courses
          • Simulation Center
          • Continuing Education & Professional Development Home
          • Continuing Professional Education/Conferences
          • Administrative Internships & Fellowships
          • Cancer Survivorship Professional Education
          • Leadership Institute
          • Patient Home Visits
          • Education Resources Home
          • Alumni Relations
          • Education Design Services
          • Awards & Recognitions
          • Academic Mentoring Council
          • Why UT MD Anderson & Houston
          • Outreach Programs Home
          • Project ECHO
          • Observer Programs
          • Comparative Effectiveness Training (CERTaIN)
          • Faculty Speakers Bureau
        • Apply to SHP

          Choose from 12 allied health programs at School of Health Professions.

          Research Trainees

          View open postdoctoral and other research trainee positions.

          GME Fellowships

          Learn about our graduate medical education residency and fellowship opportunities.

      Wai Chin Foo Image

      Wai Chin Foo, M.D.

      Department of Anatomical Pathology, Division of Pathology-Lab Medicine Div

      About Dr. Wai Chin Foo

      My primary role is to provide pathology support for collaborative translational and clinical studies involving gastrointestinal, pancreaticobiliary, and hepatic malignancies. I have a broad background in anatomic pathology with specific training in general oncologic pathology as well as additional sub-specialty training and expertise in gastrointestinal, pancreaticobiliary, and hepatic pathology. As a result of my extensive training, I am experienced in interpreting histology and immunohistochemistry, including in situ hybridization assays routinely used in my clinical practice. The current application is in my area of expertise and interest and builds on my prior work in pancreaticobiliary cancers.
      Read More

      Present Title & Affiliation

      Primary Appointment

      Professor, Anatomic Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas

      Dual/Joint/Adjunct Appointment

      Professor, Anatomic Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas

      Education & Training

      Degree-Granting Education

      2006University of Alabama School of Medicine, Birmingham, Alabama, US, MD
      2002Birmingham Southern College, Birmingham, Alabama, US, Bachelor of Science

      Postgraduate Training

      2020-2021Leadership Training, LEADing Others, The University of Texas MD Anderson Cancer Center, Houston, Texas
      2018-2018EPIC Beaker Training, Pathologist Builder, Epic University, Verona, Wisconsin
      2011-2012Clinical Fellowship, Gastrointestinal and Liver Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas
      2010-2011Clinical Fellowship, Surgical Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas
      2009-2010Clinical Fellowship, Surgical Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
      2006-2009Clinical Residency, Anatomic Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts

      Licenses & Certifications

      2011American Board of Pathology - Diplomate, Anatomic Pathology
      2010Texas Medical Board - Full Medical License
      2010Commonwealth of Massachusetts - Full Medical License

      Experience & Service

      Faculty Academic Appointments

      Associate Professor, Anatomic Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2018 - 2024

      Assistant Professor, Anatomic Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2012 - 2018

      Administrative Appointments/Responsibilities

      Deputy Department Chair, Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2023 - Present

      Medical Director, Imaging Lab, Anatomic Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2020 - 2024

      Committee Co-Chair, Anatomic Pathology Laboratory Information System (AP-LIS) Steering Committee, The University of Texas, M.D. Anderson Cancer Center, Houston, TX, 2018 - 2018

      Committee Chair, Gastrointestinal & Liver Fellowship Program Evaluation Committee, Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2015 - 2021

      Committee Chair, Gastrointestinal & Liver Fellowship Clinical Competency Committee, Pathology, The University of Texas, M.D. Anderson Cancer Center, Houston, TX, 2015 - 2021

      Chief Resident, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 2008 - 2009

      Other Professional Positions

      Expert Advisory Board Member, H. pylori IDN Research Project (HIRP) Working Group, Otsuka Pharmaceuticals, Houston, TX, 2017

      Clinical Consultant, Gastrointestinal Pathology, Cancer Network, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, 2016 - Present

      Member, The Cancer Genome Atlas (TCGA) Cholangiocarcinoma Analysis Working Group External Pathology Committee, Bethesda, MD, 2015 - 2017

      Resident Member, The CAP Foundation, Grants sub-committee, Boston, MA, 2008 - 2009

      International Pathology Coordinator, Partners in Health, Boston, MA, 2006 - 2010

      Intramural Institutional Committee Activities

      Member, Division of Pathology & Laboratory Medicine Travel Policy Committee, The University of Texas MD Anderson Cancer Center, 2025 - Present

      Extramural Institutional Committee Activities

      Member (Alternate), Beaker Executive Committee, The University of Texas MD Anderson Cancer Center, 2022 - Present

      Member, Samuel J. Hassenbusch PRS Leadership & Institutional Service Award (LISA) Committee, The University of Texas MD Anderson Cancer Center, 2021 - 2021

      Member, AP Beaker Steering Committee, The University of Texas MD Anderson Cancer Center, 2020 - Present

      Member, Clinical Genomics Council, The University of Texas MD Anderson Cancer Center, 2020 - Present

      Member, Division of Pathology & Laboratory Medicine (DP&LM) Digital Pathology Workforce Group, The University of Texas MD Anderson Cancer Center, 2020 - Present

      Member, Physician Referral Service (PRS) Clinical Revenue Cycle Committee, The University of Texas MD Anderson Cancer Center, 2019 - 2021

      Member, AP Beaker (Adoption) Steering Committee, The University of Texas MD Anderson Cancer Center, 2018 - 2020

      Member, EHR Provider Experience Committee, The University of Texas MD Anderson Cancer Center, 2018 - 2019

      Officer, Electronic Health Record (EHR) Officer Committee, The University of Texas MD Anderson Cancer Center, 2018 - 2024

      Member, Administrative Support Action Plan Committee, The University of Texas MD Anderson Cancer Center, 2018 - 2019

      Senator, Faculty Senate, The University of Texas MD Anderson Cancer Center, 2016 - 2021

      Pathologist, Pathology Rare Tumors Working Group, The University of Texas MD Anderson Cancer Center, 2016 - Present

      Member, Fellow Lecture Award Committee, The University of Texas MD Anderson Cancer Center, 2015 - 2019

      Member, Gastrointestinal & Liver Pathology Fellowship Clinical Competency Committee, The University of Texas MD Anderson Cancer Center, 2015 - Present

      Member, Gastrointestinal & Liver Pathology Fellowship Program Evaluation Committee, The University of Texas MD Anderson Cancer Center, 2015 - Present

      Member, General Surgical Pathology Fellowship Clinical Competency Committee, The University of Texas MD Anderson Cancer Center, 2015 - 2020

      Member, General Surgical Pathology Fellowship Program Evaluation Committee, The University of Texas MD Anderson Cancer Center, 2015 - 2020

      Member, Oncology Steering Committee (OneConnect Adoption), The University of Texas MD Anderson Cancer Center, 2015 - 2016

      Member, Frozen Section/Intraoperative Lab Committee, The University of Texas MD Anderson Cancer Center, 2014 - Present

      Honors & Awards

      2022 - 2024Multi-Year Appointment Award, The University of Texas, M.D. Anderson Cancer Center
      2003Arnold G. Diethelm Fellow, University of Alabama School of Medicine
      2002 - 2006Paul W. Burleson Scholar, University of Alabama School of Medicine
      2002Magna Cum Laude, Birmingham Southern College

      Professional Memberships

      Houston Society of Clinical Pathologists

      2021 - Present

      Digital Pathology Association

      2021 - Present

      Texas Society of Pathologists

      2016 - Present

      Pancreatobiliary Pathology Society

      2016 - Present

      Texas Medical Association

      2012 - Present

      United States and Canadian Academy of Pathology

      2008 - Present

      College of American Pathologists

      2006 - Present

      Selected Presentations & Talks

      Local Presentations

      1. 2025. Appendiceal Mucinous Neoplasms & Pseudomyxoma Peritonei: Updates. Surgical Pathology Lecture Series (MOSP1703). Houston, Texas, US.
      2. 2024. Primary Liver Tumors. Invited. Surgical Pathology Citywide Conference. Houston, Texas, US.
      3. 2022. Appendiceal Mucinous Neoplasms & Pseudomyxoma Peritonei: Updates. Surgical Pathology Lecture Series (MOSP1703). Houston, TX, US.
      4. 2022. Update on Pancreatic Neuroendocrine Neoplasms. Surgical Pathology Lecture Series (MOSP1703). Houston, TX, US.
      5. 2020. PD-L1 in Gastrointestinal Carcinomas and Complications from Checkpoint Inhibition. Conference. PD-L1 in Gastrointestinal Carcinomas and Complications from Checkpoint Inhibition. Houston, TX, US.
      6. 2019. Immune Checkpoint Inhibitors in GI Carcinomas: Biomarkers and Complications. Conference. Immune Checkpoint Inhibitors in GI Carcinomas: Biomarkers and Complications. Houston, TX, US.
      7. 2019. Appendiceal Mucinous Neoplasms & Pseudomyxoma Peritonei: Consensus & Updates. Conference. Appendiceal Mucinous Neoplasms & Pseudomyxoma Peritonei: Consensus & Updates. Houston, TX, US.
      8. 2017. Appendiceal Mucinous Neoplasms & Pseudomyxoma Peritonei: Moving Towards Consensus. Conference. Appendiceal Mucinous Neoplasms & Pseudomyxoma Peritonei: Moving Towards Consensus. Houston, TX, US.
      9. 2015. Appendiceal Mucinous Neoplasms. Conference. Appendiceal Mucinous Neoplasms. Houston, TX, US.
      10. 2014. Appendiceal Mucinous Neoplasms & Pseudomyxoma Peritonei. Conference. Appendiceal Mucinous Neoplasms & Pseudomyxoma Peritonei. Houston, TX, US.

      National Presentations

      1. 2023. Considerations in Grading. Invited. Inaugural Appendix Cancer Think Tank. Nashville, Tennessee, US.
      2. 2022. CD8 Singleplex Image Analysis. Invited. CD8 Singleplex Image Analysis, US.
      3. 2019. BRAF V600E and PD-L1 Biomarker Analysis in Cutaneous Oncology and Therapy-related Skin and GI toxicities: Review, Update, and Pitfalls!. Conference. BRAF V600E and PD-L1 Biomarker Analysis in Cutaneous Oncology and Therapy-related Skin and GI toxicities: Review, Update, and Pitfalls!. Phoenix, AZ, US.
      4. 2017. High level microsatellite instability in appendiceal carcinomas. Conference. High level microsatellite instability in appendiceal carcinomas. San Antonio, TX, US.
      5. 2016. Completion resections of low grade appendiceal mucinous neoplasm with extra-appendiceal mucin and appendiceal margin involvement. Conference. Completion resections of low grade appendiceal mucinous neoplasm with extra-appendiceal mucin and appendiceal margin involvement. Seattle, WA, US.
      6. 2011. FAP-assodated desmoid fibromatosis: a comparison to their sporadic counterparts. Conference. FAP-assodated desmoid fibromatosis: a comparison to their sporadic counterparts. San Antonio, TX, US.
      7. 2010. Immunohistochemical staining for TLE1 distinguishes synovial sarcoma from histologic mimics. Conference. Immunohistochemical staining for TLE1 distinguishes synovial sarcoma from histologic mimics. Washington, DC, US.
      8. 2009. Partners in pathology: a model for department-wide educational experience. Conference. Partners in pathology: a model for department-wide educational experience. Boston, MA, US.
      9. 2008. The accuracy of pretreatment biopsy of pleural malignant mesothelioma in predicting histopathologic type in extrapleural pneumonectomy. Conference. The accuracy of pretreatment biopsy of pleural malignant mesothelioma in predicting histopathologic type in extrapleural pneumonectomy. Denver, CO, US.

      International Presentations

      1. 2025. Pancreatic Neuroendocrine Tumors: Evolving Concepts. Invited. Indonesia Pathology ECHO (IPE). Houston, US.
      2. 2023. Update in Pancreatic Neuroendocrine Neoplasms. Conference. Update in Pancreatic Neuroendocrine Neoplasms. Penang, MY.
      3. 2023. Pancreatic Cysts: the Good, the Bad, & the Challenging. Conference. Pancreatic Cysts: the Good, the Bad, & the Challenging. Penang, MY.
      4. 2019. Interesting Pancreatic Cases. Conference. Interesting Pancreatic Cases. Malacca, MY.
      5. 2019. Updates in Pancreatic Mucinous Neoplasms. Conference. Updates in Pancreatic Mucinous Neoplasms. Malacca, MY.
      6. 2019. Updates in Pancreatic Neuroendocrine Neoplasms. Conference. Updates in Pancreatic Neuroendocrine Neoplasms. Malacca, MY.
      7. 2019. GI Complications in the Age of Immunotherapy. Conference. GI Complications in the Age of Immunotherapy. Mexico City, MX.
      8. 2019. Gastric Cancer: Updates & Biomarkers. Conference. Gastric Cancer: Updates & Biomarkers. Mexico City, MX.
      9. 2018. Appendiceal Mucinous Neoplasms & Pseudomyxoma Peritonei: Consensus & Updates. Conference. Appendiceal Mucinous Neoplasms & Pseudomyxoma Peritonei: Consensus & Updates. San Salvador, SV.
      10. 2017. Appendiceal Mucinous Neoplasms & Pseudomyxoma Peritonei: Moving Towards Consensus. Conference. Appendiceal Mucinous Neoplasms & Pseudomyxoma Peritonei: Moving Towards Consensus. Bangkok, TH.
      11. 2017. GI Complications in the Age of Immunotherapy. Conference. GI Complications in the Age of Immunotherapy. Bangkok, TH.
      12. 2012. Loss of PTEN expression in pancreatic ductal adenocarcinoma is associated with poor survival. Conference. Loss of PTEN expression in pancreatic ductal adenocarcinoma is associated with poor survival. Vancouver, CA.
      13. 2012. Muscularis mucosae duplication and musculo-fibrous anomalies in squamous dysplasia of the esophagus. Conference. Muscularis mucosae duplication and musculo-fibrous anomalies in squamous dysplasia of the esophagus. Cape Town, ZA.
      Read More
      Less

      Grant & Contract Support

      Date: 2022 - 2023
      Title:S20-089F2 ComboMATCH
      Funding Source:NIH/NCI
      Role:Co-PI
      ID:FP00018431
      Date: 2022 - 2023
      Title:S20-089F1 MDNet - Site Management
      Funding Source:NIH/NCI
      Role:Collaborator
      ID:60653
      Date: 2019 - 2026
      Title:Randomized Study Evaluating Molecular Profiling and Targeted Agents in Metastatic Cancer: Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT II)
      Funding Source:Tempus Labs, Inc
      Role:Co-PI
      ID:PA12-1161
      Date: 2018 - 2025
      Title:An Exploratory Study of Nivolumab with or without Ipilimumab According to Tumor CD8 Expression in Patients with Advanced Cancer
      Funding Source:Parker Institute for Cancer
      Role:Principal Investigator-MDACC
      ID:2017-0446
      Date: 1998 - 2018
      Title:Cancer Center Support (CORE) Grant
      Funding Source:NIH/NCI
      Role:Co-I
      ID:3P0CA016672-41S9

      Selected Publications

      Peer-Reviewed Articles

      1. Chowdhury S, Ito I, Pattalachinti VK, G Yousef AM, G Yousef MM, Khoury SE, Hornstein N, Seldomridge AN, Hong D, Overman MJ, Taggart MW, Foo WC, Helmink B, Fournier KF, Shen JP. KRAS inhibition is an effective therapy for appendiceal adenocarcinoma. J Hematol Oncol, 2026. PMID: 42393724.
      2. Elzamly, S, Al-Attar, MM, Taggart, MW, Foo, WC, Ajani, JA, Maru, D, Chatterjee, D. Frequent synaptophysin expression in SMARCA4-deficient undifferentiated carcinoma of the oesophagus. J Clin Pathol 79(4):229-237, 2026. e-Pub 2026. PMID: 41592958.
      3. Seldomridge, AN, White, MG, Scally, CP, Royal, RE, Routbort, MJ, Iorgulescu, JB, Overman, MJ, Lee, SM, Foo, WC, Taggart, MW, Song, Y, Mansfield, PF, Fournier, KF, Shen, JY, Helmink, BA. ASO Visual Abstract: Clinicopathologic and Molecular Characteristics of High-Grade Appendiceal Mucinous Neoplasms. Ann Surg Oncol 33(3):2439-2440, 2026. e-Pub 2026. PMID: 41366166.
      4. Lapelusa, M, Qiao, W, Iorgulescu, B, San Lucas, FA, Patel, KP, Bhamidipati, D, Thomas, J, You, YN, Foo, WC, Maru, D, Thirumurthi, S, Morris, VK, Kopetz, S, Overman, MJ, Ludford, K. Long-Term Efficacy of Pembrolizumab and the Clinical Utility of ctDNA in Locally Advanced dMMR/MSI-H Solid Tumors. Nat Commun 16(1), 2025. e-Pub 2025. PMID: 40374594.
      5. Seldomridge AN, White MG, Scally C, Royal RE, Routbort M, Iorgulescu J, Overman MJ, Lee SM, Foo WC, Taggart MW, Song Y, Mansfield PF, Fournier KF, Shen JP, Helmink BA. Clinicopathologic and Molecular Characteristics of High-Grade Appendiceal Mucinous Neoplasms. Ann Surg Oncol 33(3):2376-2387, 2025. e-Pub 2025. PMID: 41225239.
      6. Morris VK, Parseghian CM, Bahrambeigi V, Abdelfattah N, Xiao L, Agrawal A, Lin K, Raghav KPS, Wolff RA, Dasari A, Huey RW, Kee BK, Overman MJ, Willis JA, Le PH, Escano M, Baig YC, Pan K, Menter D, Tam AL, Foo WC, Shen L, Lee HM, Gallup TD, Margain C, Gallup D, Rajapakshe KI, Guerrero PA, Wang J, Corcoran RB, Maitra A, Yun K, Kopetz S. Phase 1/2 trial of encorafenib, cetuximab, and nivolumab in microsatellite stable BRAF(V600E) metastatic colorectal cancer. Cancer Cell 43(11):2106-2118.e3, 2025. e-Pub 2025. PMID: 40882637.
      7. Kataoka K, Mauer M, Shiozawa M, Marreaud S, Kishi Y, Cabrieto J, Onaya H, Ducreux M, Suto T, Kang HC, Matsuhashi N, Fung A, Yasui M, Rivoire M, Tonooka T, Troisi RI, Nakamura K, Stattner S, Kinugasa Y, Foo WC, Desolneux G, Bonhomme B, Ikeda M, Caballero C, Lordick F, Kanemitsu Y, Evrard S. Diagnostic Accuracy of Imaging in Assessing Nonviability of Disappearing Colorectal Liver Metastasis. JAMA Surg 160(11):1212-1220, 2025. e-Pub 2025. PMID: 40960802.
      8. Saleem, A, Shaikh, AS, Overman, MJ, Naik, SA, Foo, WC, Vilar Sanchez, E, Triadafilopoulos, G, Raju, GS, Richards, DM. Vanished! Auto-amputated Ileal Polyp in a Patient with Lynch Syndrome. Dig Dis Sci 70(7):2292-2296, 2025. e-Pub 2025. PMID: 40266505.
      9. Peddireddy, A, Huey, RW, Wolff, RA, Lin, K, Mitchell, J, Scofield, LC, Jacob, S, Nguyen, DV, Rogers, JE, Portier, S, Foo, WC, Eng, C, Morris, VK. Clinicopathologic Features Associated with Survival for Immune Checkpoint Blockade in Patients with Metastatic Anal Cancer. Cancers 17(6), 2025. e-Pub 2025. PMID: 40149273.
      10. Tsimberidou AM, Alayli FA, Okrah K, Drakaki A, Khalil DN, Kummar S, Khan SA, Hodi FS, Oh DY, Cabanski CR, Gautam S, Meier SL, Amouzgar M, Pfeiffer SM, Kageyama R, Yang E, Spasic M, Tetzlaff MT, Foo WC, Hollmann TJ, Li Y, Adamow M, Wong P, Moore JS, Velichko S, Chen RO, Kumar D, Bucktrout S, Ibrahim R, Dugan U, Salvador L, Hubbard-Lucey VM, O'Donnell-Tormey J, Santulli-Marotto S, Butterfield LH, Da Silva DM, Fairchild J, LaVallee TM, Padron LJ, Sharma P. Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancer. J Exp Med 221(10), 2024. e-Pub 2024. PMID: 39190534.
      11. Sun H, Kang EY, Chen H, Sweeney KJ, Suchko M, Wu Y, Wen J, Krishnamurthy S, Albarracin CT, Ding QQ, Foo WC, Sahin AA. Immunohistochemical assessment of HER2 low breast cancer: interobserver reproducibility and correlation with digital image analysis. Breast Cancer Res Treat 205(2):403-411, 2024. e-Pub 2024. PMID: 38441847.
      12. Yousef, A, Yousef, M, Zeineddine, MA, More, A, Fanaeian, M, Chowdhury, S, Knafl, M, Edelkamp, P, Ito, I, Gu, Y, Pattalachinti, V, Naini, ZA, Zeineddine, F, Peterson, J, Alfaro, KD, Foo, WC, Jin, J, Bhutiani, N, Higbie, V, Scally, CP, Kee, BK, Kopetz, S, Goldstein, D, Strach, M, Williamson, A, Aziz, O, Barriuso, J, Uppal, A, White, MG, Helmink, BA, Fournier, KF, Raghav, KS, Taggart, MW, Overman, MJ, Shen, JY. Serum Tumor Markers and Outcomes in Patients With Appendiceal Adenocarcinoma. JAMA Network Open 7(2):e240260, 2024. e-Pub 2024. PMID: 38416491.
      13. White, MG, Bhutiani, N, Helmink, BA, Taggart, MW, Foo, WC, Mansfield, PF, Fournier, KF, Scally, CP. ASO Visual Abstract: Treatment Variation and Long-Term Outcomes of Low-Grade Appendiceal Neoplasms. Ann Surg Oncol 30(13):8176, 2023. e-Pub 2023. PMID: 37728822.
      14. Dhingra, S, Taggart, MW, Foo, WC, Rashid, A, Heredia, MM, May, SB, Buren, GV, Fisher, WE, Wang, H. Interobserver Variability and Challenges in Intraoperative Frozen Section Evaluation of Pancreatic Margins in Pancreatectomy Specimens. Ann Clin Lab Sci 53(6):847-860, 2023. e-Pub 2023. PMID: 38182140.
      15. Shen JP, Yousef AM, Zeineddine FA, Zeineddine MA, Tidwell RS, Beaty KA, Scofield LC, Rafeeq S, Hornstein N, Lano E, Eng C, Matamoros A, Foo WC, Uppal A, Scally C, Mansfield P, Taggart M, Raghav KP, Overman MJ, Fournier K. Efficacy of Systemic Chemotherapy in Patients with Low-grade Mucinous Appendiceal Adenocarcinoma: A Randomized Crossover Trial. JAMA Netw Open 6(6):e2316161, 2023. e-Pub 2023. PMID: 37261831.
      16. Ludford K, Ho WJ, Thomas JV, Raghav KPS, Murphy MB, Fleming ND, Lee MS, Smaglo BG, You YN, Tillman MM, Kamiya-Matsuoka C, Thirumurthi S, Messick C, Johnson B, Vilar E, Dasari A, Shin S, Hernandez A, Yuan X, Yang H, Foo WC, Qiao W, Maru D, Kopetz S, Overman MJ. Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors. J Clin Oncol 41(12):JCO2201351, 2023. e-Pub 2023. PMID: 36623241.
      17. Hernandez S, Das P, Holliday EB, Shen L, Lu W, Johnson B, Messick CA, Taniguchi CM, Skibber J, Ludmir EB, You YN, Li Smith G, Bednarski B, Kostousov L, Koay EJ, Minsky BD, Tillman M, Portier S, Eng C, Koong AC, Chang GJ, Foo WC, Wang J, Solis Soto L, Morris VK. Differential Spatial Gene and Protein Expression Associated with Recurrence Following Chemoradiation for Localized Anal Squamous Cell Cancer. Cancers 15(6):1701, 2023. e-Pub 2023. PMID: 36980587.
      18. Zhou Y, Medik YB, Patel B, Zamler DB, Chen S, Chapman T, Schneider S, Park EM, Babcock RL, Chrisikos TT, Kahn LM, Dyevoich AM, Pineda JE, Wong MC, Mishra AK, Cass SH, Cogdill AP, Johnson DH, Johnson SB, Wani K, Ledesma DA, Hudgens CW, Wang J, Wadud Khan MA, Peterson CB, Joon AY, Peng W, Li HS, Arora R, Tang X, Raso MG, Zhang X, Foo WC, Tetzlaff MT, Diehl GE, Clise-Dwyer K, Whitley EM, Gubin MM, Allison JP, Hwu P, Ajami NJ, Diab A, Wargo JA, Watowich SS. Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltration. J Exp Med 220(2), 2023. e-Pub 2023. PMID: 36367776.
      19. Erstad DJ, Robinson KA, Beaty K, Rafeeq S, Chiang YJ, Raghav K, Shen JP, Overman MJ, Foo WC, Taggart MW, Mansfield PF, Royal RE, Fournier KF, Scally CP. Prognostic significance of acellular mucin in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) for appendiceal neoplasms. Langenbecks Arch Surg 408(1):110, 2023. e-Pub 2023. PMID: 36853519.
      20. Hailemichael Y, Johnson DH, Abdel-Wahab N, Foo WC, Bentebibel SE, Daher M, Haymaker C, Wani K, Saberian C, Ogata D, Kim ST, Nurieva R, Lazar AJ, Abu-Sbeih H, Fa'ak F, Mathew A, Wang Y, Falohun A, Trinh V, Zobniw C, Spillson C, Burks JK, Awiwi M, Elsayes K, Soto LS, Melendez BD, Davies MA, Wargo J, Curry J, Yee C, Lizee G, Singh S, Sharma P, Allison JP, Hwu P, Ekmekcioglu S, Diab A. Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. Cancer Cell 40(5):509-523.e6, 2022. e-Pub 2022. PMID: 35537412.
      21. Carapeto F, Bozorgui B, Shroff RT, Chagani S, Solis Soto L, Foo WC, Wistuba I, Meric-Bernstam F, Shalaby A, Javle M, Korkut A, Kwong LN. The Immunogenomic Landscape of Resected Intrahepatic Cholangiocarcinoma. Hepatology 75(2):297-308, 2022. e-Pub 2022. PMID: 34510503.
      22. Corsini EM, Foo WC, Mitchell KG, Zhou N, Maru DM, Ajani JA, Hofstetter WL, Working Group EA, Correa AM, Antonoff MB, Lin SH, Mehran RJ, Rajaram R, Rice DC, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL. Esophageal adenocarcinoma with any component of signet ring cells portends poor prognosis and response to neoadjuvant therapy. J Thorac Cardiovasc Surg 162(5):1404-1412.e2, 2021. e-Pub 2020. PMID: 33010880.
      23. Marcus R, Ferri-Borgogno S, Hosein A, Foo WC, Ghosh B, Zhao J, Rajapakshe K, Brugarolas J, Maitra A, Gupta S. Oncogenic KRAS Requires Complete Loss of BAP1 Function for Development of Murine Intrahepatic Cholangiocarcinoma. Cancers (Basel) 13(22), 2021. e-Pub 2021. PMID: 34830866.
      24. Khurana S, Abu-Sbeih H, Ma W, Qiao W, Foo WC, Richards DM, Thomas AS, Khan A, Zhang HC, Wang Y. Clinical Characteristics and Outcomes of Eosinophilic Colitis in Patients With Cancer. Am J Clin Oncol 44(8):395-401, 2021. e-Pub 2021. PMID: 34091476.
      25. Kanikarla Marie P, Haymaker C, Parra ER, Kim YU, Lazcano R, Gite S, Lorenzini D, Wistuba II, Tidwell RSS, Song X, Foo WC, Maru DM, Chun YS, Futreal A, Kee B, Menter D, Solis L, Tzeng CW, Parseghian C, Raghav K, Morris V, Chang CC, Jenq R, Tam A, Bernatchez C, Kopetz S, Vauthey JN, Overman MJ. Pilot Clinical Trial of Perioperative Durvalumab and Tremelimumab in the Treatment of Resectable Colorectal Cancer Liver Metastases. Clin Cancer Res 27(11):3039-3049, 2021. e-Pub 2021. PMID: 33811152.
      26. Hester, R, Advani, S, Rashid, A, Holliday, EB, Messick, C, Das, P, You, YN, Taniguchi, C, Koay, EJ, Bednarski, BK, Rodriguez-Bigas, MA, Skibber, JM, Wolff, RA, Chang, GJ, Minsky, B, Foo, WC, Rothschild, ND, Morris, VK, Eng, C. CEA as a blood-based biomarker in anal cancer. Oncotarget 12(11):1037-1045, 2021. e-Pub 2021. PMID: 34084278.
      27. Hester R, Advani S, Rashid A, Holliday E, Messick C, Das P, You Y, Taniguchi C, Koay EJ, Bednarski B, Rodriguez-Bigas M, Skibber J, Wolff R, Chang GJ, Minsky BD, Foo WC, Rothschild N, Morris VK, Eng C. CEA as a blood-based biomarker in anal cancer. Oncotarget 12(11):1037-1045, 2021. e-Pub 2021. PMID: 34084278.
      28. Ludford K, Cohen R, Svrcek M, Foo WC, Colle R, Parc Y, Thomas JV, Morris VK, Kopetz S, Chang GJ, Overman M, Andre T. Pathological tumor response following immune checkpoint blockade for deficient mismatch repair advanced colorectal cancer. J Natl Cancer Inst 113(2):208-211, 2021. e-Pub 2021. PMID: 32294214.
      29. Coronel M, Lanke G, Campbell D, Coronel E, Tzeng CD, Foo WC, Lee JH. Performing endoscopic retrograde cholangiopancreatography and endoscopic ultrasound for management of malignant bile duct obstruction in a patient with a situs inversus totalis. ACG Case Rep J 7(12), 2020. e-Pub 2020. PMID: 33324708.
      30. Tang T, Abu-Sbeih H, Ma W, Lu Y, Luo W, Foo WC, Richards DM, Halperin DM, Ge PS, Wang Y. Gastrointestinal Injury Related to Antiangiogenesis Cancer Therapy. Clin Colorectal Cancer 19(3):117-123, 2020. e-Pub 2020. PMID: 32284253.
      31. Toomey S, Gunther J, Carr A, Weksberg DC, Thomas V, Salvucci M, Bacon O, Sherif EM, Fay J, Kay EW, Sheehan KM, McNamara DA, Sanders KL, Mathew G, Breathnach OS, Grogan L, Morris PG, Foo WC, You YN, Prehn JH, O'Neill B, Krishnan S, Hennessy BT, Furney SJ. Genomic and Transcriptomic Characterisation of Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer. Cancers (Basel) 12(7), 2020. e-Pub 2020. PMID: 32640573.
      32. Raghav K, Shen JP, Jacome AA, Guerra JL, Scally CP, Taggart MW, Foo WC, Matamoros A, Shaw KR, Fournier K, Overman MJ, Eng C. Integrated clinico-molecular profiling of appendiceal adenocarcinoma reveals a unique grade-driven entity distinct from colorectal cancer. Br J Cancer 123(1262-1270), 2020. e-Pub 2020. PMID: 32733093.
      33. Ge PS, Angsuwatcharakon P, Chang GJ, Foo WC, Tillman MM, Aihara H. The suture pulley countertraction method for challenging rectal endoscopic submucosal dissection. VideoGIE 5(5):210-212, 2020. e-Pub 2020. PMID: 32426573.
      34. Abu-Sbeih H, Ali FS, Chen E, Mallepally N, Luo W, Lu Y, Foo WC, Qiao W, Okhuysen PC, Adachi JA, Hachem RY, Altan M, Jenq RR, Wang Y. Neutropenic Enterocolitis: Clinical Features and Outcomes. Dis Colon Rectum 63(3):381-388, 2020. e-Pub 2020. PMID: 31842164.
      35. Lopez A, Harada K, Chen HC, Bhutani MS, Weston B, Lee JH, Maru DM, Foo WC, Rogers JE, Thomas I, Amlashi FG, Blum-Murphy MA, Rice DC, Zhao M, Hofstetter WL, Nguyen Q, Ajani JA. Taxane-based or platinum-based combination chemotherapy given concurrently with radiation followed by surgery resulting in high cure rates in esophageal cancer patients. Medicine (Baltimore) 99(9):e19295, 2020. e-Pub 2020. PMID: 32118743.
      36. Chirieac LR, Hung YP, Foo WC, Hofer MD, VanderLaan PA, Richards WG, Sugarbaker DJ, Bueno R. Diagnostic value of biopsy sampling in predicting histology in patients with diffuse malignant pleural mesothelioma. Cancer, 2019. e-Pub 2019. PMID: 31390057.
      37. Abu-Sbeih H, Tang T, Ali FS, Luo W, Neelapu SS, Westin JR, Okhuysen PC, Foo WC, Curry JL, Richards DM, Ge PS, Wang Y. Gastrointestinal adverse events observed after chimeric antigen receptor T-cell therapy. Am J Clin Oncol 42(10):789-796, 2019. e-Pub 2019. PMID: 31478934.
      38. Hui L, Rashid A, Foo WC, Katz MH, Chatterjee D, Wang H, Fleming JB, Tamm EP, Wang H. Significance of T1a and T1b carcinoma arising in mucinous cystic neoplasm of pancreas. Am J Surg Pathol, 2018. e-Pub 2018. PMID: 29462092.
      39. Sagebiel TL, Mohamed A, Matamoros A, Taggart MW, Doamekpor F, Raghav KP, Mann GN, Mansfield PF, Eng C, Royal RE, Foo WC, Ensor JE, Fournier KF, Overman MJ. Utility of Appendiceal Calcifications Detected on Computed Tomography as a Predictor for an Underlying Appendiceal Epithelial Neoplasm. Ann Surg Oncol 24(12):3667-3672, 2017. e-Pub 2017. PMID: 28831698.
      40. Morris V, Rao X, Pickering C, Foo WC, Rashid A, Eterovic A, Kim TB, Chen K, Wang J, Shaw K, and Eng C. Comprehensive Genomic Profiing of Metastatic Squamous Cell Carcinoma of the Anal Canal. Mol Cancer Res 15(11), 2017. e-Pub 2017. PMID: 28784613.
      41. Chatterjee D, Katz MH, Foo WC, Sundar M, Wang H, Varadhachary GR, Wolff RA, Lee JE, Maitra A, Fleming JB, Rashid A, Wang H. Prognostic Significance of New AJCC Tumor Stage in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Therapy. Am J Surg Pathol 41(8):1097-1104, 2017. e-Pub 2017. PMID: 28614206.
      42. Morris VK, Salem ME, Nimeiri H, Iqbal S, Singh P, Ciombor K, Polite B, Deming D, Chan E, Wade JL, Xiao L, Bekaii-Saab T, Vence L, Blando J, Mahvash A, Foo WC, Ohaji C, Pasia M, Bland G, Ohinata A, Rogers J, Mehdizadeh A, Banks K, Lanman R, Wolff RA, Streicher H, Allison J, Sharma P, Eng C. Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. Lancet Oncol 18(4):446-453, 2017. e-Pub 2017. PMID: 28223062.
      43. Farshidfar F, Zheng S, Gingras MC, Newton Y, Shih J, Robertson AG, Hinoue T, Hoadley KA, Gibb EA, Roszik J, Covington KR, Wu CC, Shinbrot E, Stransky N, Hegde A, Yang JD, Reznik E, Sadeghi S, Pedamallu CS, Ojesina AI, Hess JM, Auman JT, Rhie SK, Bowlby R, Borad MJ, Atlas Network CG, Zhu AX, Stuart JM, Sander C, Akbani R, Cherniack AD, Deshpande V, Mounajjed T, Foo WC, Torbenson MS, Kleiner DE, Laird PW, Wheeler DA, McRee AJ, Bathe OF, Andersen JB, Bardeesy N, Roberts LR, Kwong LN. Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. Cell Rep 18(11):2780-2794, 2017. e-Pub 2017. PMID: 28297679.
      44. Khan M, Korphaisarn K, Saif A, Foo WC, Kopetz S. Early-Onset Signet-Ring Cell Adenocarcinoma of the Colon: A Case Report and Review of the Literature. Case Rep Oncol Med 2017, 2017. e-Pub 2017. PMID: 28326211.
      45. Gutierrez C, Kebriaei P, Turner KA, Yemelyanova A, Ariza-Heredia EJ, Foo WC. A unique presentation of acute liver failure from herpes simplex virus hepatitis. Transpl Infect Dis 18(4):592-4, 2016. e-Pub 2016. PMID: 27222930.
      46. Rojas A, Zhang P, Wang Y, Foo WC, Muñoz NM, Xiao L, Wang J, Gores GJ, Hung MC, Blechacz B. A Positive TGF-β/c-KIT Feedback Loop Drives Tumor Progression in Advanced Primary Liver Cancer. Neoplasia 18(6):371-86, 2016. e-Pub 2016. PMID: 27292026.
      47. Sathyanarayanan V, Foo WC, Fanale M, Westin J. Deeper Insights Into Vanishing Bile Duct Syndrome in Lymphoma: A Perplexing Entity. Clin Lymphoma Myeloma Leuk 16(5):e65-70, 2016. e-Pub 2016. PMID: 27050323.
      48. Overman MJ, Eng C, Raghav K, Matamoros A, Taggart M, Foo WC, Fournier K. Challenges of efficacy assessments in pseudomyxoma peritonea. Oncologist 20(3):e3-4, 2015. e-Pub 2015. PMID: 25745054.
      49. Foo WC, Wang H, Prieto VG, Fleming JB, Abraham SC. Squamoid cystosis of pancreatic ducts: a variant of a newly-described cystic lesion, with evidence for an obstructive etiology. Rare Tumors 6(3):5286, 2014. e-Pub 2014. PMID: 25276318.
      50. Liu C, Karam R, Zhou Y, Su F, Ji Y, Li G, Xu G, Lu L, Wang C, Song M, Zhu J, Wang Y, Zhao Y, Foo WC, Zuo M, Valasek MA, Javle M, Wilkinson MF, Lu Y. The UPF1 RNA surveillance gene is commonly mutated in pancreatic adenosquamous carcinoma. Nat Med 20(6):596-8, 2014. e-Pub 2014. PMID: 24859531.
      51. Foo WC, Rashid A, Wang H, Katz MH, Lee JE, Pisters PW, Wolff RA, Abbruzzese JL, Fleming JB, Wang H. Loss of phosphatase and tensin homolog expression is associated with recurrence and poor prognosis in patients with pancreatic ductal adenocarcinoma. Hum Pathol 44(6):1024-30, 2013. e-Pub 2013. PMID: 23260327.
      52. Colombo C, Foo WC, Whiting D, Young ED, Lusby K, Pollock RE, Lazar AJ, Lev D. FAP-related desmoid tumors: a series of 44 patients evaluated in a cancer referral center. Histol Histopathol 27(5):641-9, 2012. e-Pub 2012. PMID: 22419028.
      53. Krishna SG, Stroehlein JR, Foo WC, Suzuki R, Reddy SR, Bhutani MS. Iatrogenic infection of a colonic cystic lymphangioma following cold-forceps biopsy. Endoscopy 44(Supplement S2):E104-5, 2012. e-Pub 2012. PMID: 22477167.
      54. Foo WC, Cruise M, Wick MR, Hornick JL. Immunohistochemical staining for TLE1 distinguishes synovial sarcoma from histologic mimics. Am J Clin Pathol 135(6):839-844, 2011. e-Pub 2011. PMID: 21571956.
      55. Carlson JW, Lyon E, Walton D, Foo WC Sievers AC, Shulman LN, Farmer P, Nose V, Jr MD. Partners in pathology: a collaborative model to bring pathology to resource poor settings. Am J Surg Pathol 34(1):118-123, 2010. e-Pub 2010. PMID: 19898229.

      Invited Articles

      1. Cox VL, Saeed Bamashmos AA, Foo WC, Gupta S, Yedururi S, Garg N, Kang HC. Lynch syndrome: genomics update and imaging review. Radiographics 38(2):483-499, 2018. e-Pub 2018.
      2. Foo WC, Liegl-Atzwanger B, Lazar AJ. Pathology of gastrointestinal stromal tumors. Clin Med Insights Pathol 5, 2012. e-Pub 2012. PMID: 22855636.

      Review Articles

      1. Brown, LM, Wilkins, SG, Bansal, VV, Su, D, Gomez-Mayorga, J, Turaga, KK, Gunderson, CG, Lee, B, Nash, G, Hays, J, Raghav, KS, Husain, AL, Kluger, MD, Zauderer, MG, Kindler, HL, Alexander, HR, Li, Y, Gao, X, Keutgen, XM, Bowne, WB, Foo, WC, Vudatha, V, Khan, U, Sarpel, U, Maduekwe, UN, Grotz, TE, Lwin, T, Jaraczewski, T, Gamblin, TC, Campbell, S, Libutti, SK, Greco, SH, Cohen, S, Yang, SR, Abdel-Misih, SR, Radomski, SN, Concors, SJ, Dineen, SP, Sherman, SK, Daniel, SK, Bagaria, SP, Butensky, SD, Naffouje, S, Patel, SH, Royal, RE, Taggart, MW, Shen, JY, Chatterjee, D, Helmink, BA, Tam, AL. Consensus Guideline for the Management of Peritoneal Mesothelioma. Ann Surg Oncol 33(6):5125-5141, 2026. e-Pub 2026. PMID: 40560500.
      2. Schultz, K, Bansal, VV, Wach, MM, Bhutiani, N, Godley, FA, Wang, JJ, Waheed, MT, Buchheit, JT, Papai, E, Campbell, S, Schleimer, LE, Su, D, Turaga, KK, Gunderson, CG, White, MG, Uppal, A, Raghav, KS, Labow, D, Sarpel, U, Shergill, A, Shen, JY, Eng, C, Foote, MB, Baumgartner, JM, Li, Y, Gao, X, Keutgen, XM, Morano, W, Bowne, WB, Luo, W, Foo, WC, Vudatha, V, Gushchin, V, Khan, U, Maduekwe, UN, Grotz, TE, Nguyen, T, Halfdanarson, TR, Lwin, T, Jaraczewski, T, Gamblin, TC, Libutti, SK, Ahrendt, SA, Greco, SH, Stein, S, Royal, RE, Taggart, MW, Maru, DM, Chatterjee, D, Helmink, BA. Consensus Guideline for the Management of Colorectal Cancer with Peritoneal Metastases. Ann Surg Oncol 33(6):5260-5282, 2026. e-Pub 2026. PMID: 40560497.
      3. Holowatyj AN, Overman MJ, Votanopoulos KI, Lowy AM, Wagner P, Washington MK, Eng C, Foo WC, Goldberg RM, Hosseini M, Idrees K, Johnson DB, Shergill A, Ward E, Zachos NC, Shelton D. Defining a 'cells to society' research framework for appendiceal tumours. Nat Rev Cancer 25(4):293-315, 2025. e-Pub 2025. PMID: 39979656.

      Other Articles

      1. Schultz KS, Bansal VV, Wach MM, Bhutiani N, Godleyth FA, Wang JJ, Waheed MT, Buchheit JT, Papai E, Campbell S, Schleimer LE, Su DG, Turaga KK, Gunderson CG, White MG, Uppal A, S Raghav KP, Labow DM, Sarpel U, Shergill AP, Shen JP, Eng C, Foote MB, Baumgartner JM, Consortium Group PSM* Consensus guideline for the management of colorectal cancer with peritoneal metastases. Cancer, 2025. PMID: 40558054.
      2. Brown LM, Wilkins SG, Bansal VV, Su DG, Gomez-Mayorga J, Turaga KK, Gunderson CG, Lee B, Nash GM, Hays JL, Raghav KP, Husain AL, Kluger MD, Zauderer MG, Kindler HL, Alexander H, Consortium Group PSM* Consensus guideline for the management of peritoneal mesothelioma. Cancer 131(13):35868, 2025. PMID: 40558081.

      Abstracts

      1. Elzamly S, Al-Attar M, Taggart M, Foo WC, Maru D, Chatterjee D. SMARCA4-Deficient Carcinoma of the Esophagus: Diagnostic Challenges with Synaptophysin Expression and Therapeutic Implications. Gastrointestinal Pathology:S703, 2024. e-Pub 2024.
      2. Fanaeian, M, Yousef, M, Yousef, A, Foo, WC, Taggart, MW, Beaty, K, Scally, CP, Mansfield, PF, Fournier, KF, Helmink, BA, Shen, JY. Risk of relapse after surgical resection of localized appendiceal adenocarcinoma. J Clin Oncol 42:58, 2024. e-Pub 2024.
      3. Lapelusa, M, San Lucas, FA, Iorgulescu, B, Patel, KP, You, YN, Foo, WC, Maru, DM, Kopetz, S, Ludford, K, Morris, VK, Overman, MJ. Circulating tumor DNA as a predictive biomarker for pathologic response after treatment with neoadjuvant immunotherapy for localized dMMR/MSI-H colorectal cancer. J Clin Oncol 42(16):3612, 2024. e-Pub 2024.
      4. Taherian M, Taggart M, Maru D, Foo WC, Rashid A, Abraham S, Chatterjee D. Clinicopathologic Features of Esophageal Adenocarcinomas with Enteroblastic Differentiation. Gastrointestinal Pathology:S638, 2023. e-Pub 2023.
      5. Lenskaya V, Jiang X, Foo WC, Abraham S, Taggart M, Walsh G, Swisher S, Ning J, Aung P, Curry J, Cho WC, Torres-Cabala C, Ivan D, Prieto V, Amaria R, Tawbi H, Nagarajan P. Primary Mucosal Melanoma of the Esophagus: Clinicopathologic and Molecular Analysis. Gastrointestinal Pathology:S590, 2023. e-Pub 2023.
      6. Chapman L, White MG, Willett A, Beaty K, Matamoros A, Taggart M, Foo WC, Scally C, Mansfield P, Malpica A, Raghav KP, Fournier KF. Neoadjuvant Chemotherapy (NACT) in Malignant Peritoneal Mesothelioma (MPeM) treated with Cytoreduction (CRS) and Heated Intraperitoneal Chemotherapy (HIPC). Eur J Surg Oncol 49(2):e60, 2023. e-Pub 2023.
      7. Peddireddy AS, Johnson B, Wolff RA, Huey R, Holliday E, Das P, Skibber JM, Portier S, Foo WC, Halperin D, Morris VK. Survival Benefit to Immunotherapy According to Site of Organ Involvement in Metastatic Anal Cancer. J Clin Oncol 41(Supplemental 4):3-3, 2023. e-Pub 2023.
      8. Alayi F, Okrah K, Tsimberidou A, Drakaki A, Khalil D, Khan S, Hodi S, Oh D, Amouzgar M, Guatam S, Kageyama R, Pfeiffer S, Meier S, Cabanski C, Da Silva D, Kumar D, Santulli-Marotto S, Tetzlaff M, Foo WC, Hollman T, Li Y, Adamow M, Wong P, Spasic M, Chen R, Bucktrout S, Fairchild J, Butterfield L, LaVallee T, Padron L, Salvador L, O'Donnell-Tormey J, Dugan U, Sharma P. AMADEUS Trial: Tumor Agnostic Pre- and Ontreatment Biomarkers of Response to Nivolumab Plus Ipilimumab Correlate with Ontreatment Tumoral T Cell Infiltration. J ImmunoTher Cancer 10:A614-A614, 2022. e-Pub 2022.
      9. Morris VK, Parseghian CM, Escano M, Johnson B, Raghav KP, Dasari A, Huey R, Overman MJ, Willis J, Lee MS, Wolff RA, Kee BK, Le P, Margain C, Gallup D, Tam A, Foo WC, Xiao L, Yun K, Kopetz S. Phase I/II Trial of Encorafenib, Cetuximab, and Nivolumab in Patients with Microsatellite Stable (MSS), BRAFV600E Metastatic Colorectal Cancer. J Clin Oncol 40(Supplemental 16):3598-3598, 2022. e-Pub 2022.
      10. Johnson DH, Hailemichael Y, Bentebibel SE, Abdel-Wahab N, Cho S, Foo WC, Wani K, Watowich SS, Ekmekcioglu S, Diab A. Th17 Inhibition with Interleukin 6 Blockade Decouples Immunotoxicity from Tumor Immunity. Cancer Res 82(Supplemental 12):4177-4177, 2022. e-Pub 2022.
      11. Taherian M, Waters R, Foo WC, Maru D, Abraham S, Rashid A, Wang H, Wei D, Taggart M, Chatterjee D. Blinded Histologic Review to Classify Grade 3 Pancreatic Epithelial Neuroendocrine Neoplasms Shows Only Slight Correlation Among Experienced Gastrointestinal Pathologists. Lab Invest 102(Supplemental 1):1234-1235, 2022. e-Pub 2022.
      12. Tong YT, Foo WC, Rashid A, Waters R, Abraham S, Chatterjee D, Taggart M. Defining Amphicrine Carcinoma of the Gastrointestinal Tract: A Single Institutional. Lab Invest 102(Supplemental 1):530-532, 2022. e-Pub 2022. PMID: 35302089.
      13. Morris VK, Parseghian CM, Escano M, Johnson B, Raghav KP, Dasari A, Huey R, Overman MJ, Willis J, Lee MS, Wolff RA, Kee BK, Shen JP, Morelli MP, Tam A, Foo WC, Xiao L, Kopetz S. Phase I/II Trial of Encorafenib, Cetuximab, and Nivolumab in Patients with Microsatellite Stable, BRAFV600E Metastatic Colorectal Cancer. J Clin Oncol 40(Supplemental 4):12-12, 2022. e-Pub 2022.
      14. Taherian, M, Waters, R, Foo, W, Maru, D, Abraham, S, Rashid, A, Wang, H, Wei, D, Taggart, M, Chatterjee, D. Pancreas, Gallbladder, Ampulla, and Extra-Hepatic Biliary Tree. United States and Canadian Academy of Pathology 102(1):1234-1235, 2022. e-Pub 2022.
      15. Diab A, Abdel-Wahab N, Johnson DH, Hailemichael Y, Foo WC, Bentebibel SE, Lizee GA, Ekmecioglu S. Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. Ann Oncol 32:S1403, 2021. e-Pub 2021.
      16. Ludford K, Raghav K, Blum-Murphy MA, Fleming ND, Nelson D, Lee MS, Smaglo BG, You YN, Tillman MM, Kamiya-Matsuoka C, Thirumurthi S, Messick C, Johnson B, Vilar E, Thomas J, Foo WC, Qiao W, Kopetz S, Overman MJ. Neoadjuvant pembrolizumab in localized/locally advanced solid tumors with mismatch repair deficiency. Ann Oncol 32:S1210, 2021. e-Pub 2021.
      17. Ludford K, Raghav K, Blum MA, Fleming ND, Nelson DA, Lee MS, Smaglo BG, You Y, Tillman MM, Kamiya-Matsuoka C, Thirumurthi S, Messick C, Johnson B, Vilar-Sanchez E, Dasari A, Thomas JV, Foo WC, Qiao W, Kopetz S, Overman MJ. Safety and efficacy of neoadjuvant pembrolizumab in mismatch repair deficient localized/locally advanced solid tumors. J Clin Oncol 39(Supplemental 15):2520-2520. e-Pub 2021.
      18. Marcus R, Hosein A, Ferri-Borgogno S, Foo WC, Rajapakshe K, Gupta S, Maitra A. The functional role of epigenetic regulators in intrahepatic cholangiocarcinoma. HPB 23:S483-S484, 2021. e-Pub 2021.
      19. Carapeto F, Soto LM, Foo WC, Lu W, Fawaz EAV, Villaseca MA, Pizarrov EA, Araya JC, Wistuba II, Milind J, Shubham P, Kwong L. Immunological and mutational landscape of gallbladder adenocarcinoma. Cancer Res 80(Supplemental 16):2658. e-Pub 2020.
      20. Khurana S, Abu-Sbeih H, Ma W, Foo WC, Zhang HC, Wang Y. Eosinophilic colitis in cancer patients. J Clin Oncol 38(Supplemental 15). e-Pub 2020.
      21. Khurana S, Abu-Sbeih H, Ma W, Foo WC, Wang Y. Eosinophilic colitis in cancer patients. Gastroenterology 158(6):S1159-S1160. e-Pub 2020.
      22. Dhingra S, Heredia MM, Taggart MW, Foo WC, Rashid A, May S, Wang H. Inter-Observer Variability and Challenges in Intraoperative Assessment of Pancreatic Resection Margins. Lab Invest 100(Supplemental 1):1641-1651, 2020. e-Pub 2020.
      23. Hailemichael Y, Johnson DH, Foo WC, Hess K, Haymaker C, Saberian C, Bentebibel B, Burton E, Wang Y, Woodman S, Hwu P, Diab A. Interleukin-6 blockade to de-couple CTLA-4 blockade colitis from anti-tumor efficacy. J Immunother Cancer 7, 2019. e-Pub 2019.
      24. Johnson DH, Hailemichael Y, Foo WC, Hess KR, Haymaker CL, Wani KM, Lazar AJ, Saberian CM, Bentebibel SE, Burton EM, Abu-Sbeih H, Wang Y, Hwu P, Diab A. Interleukin-6 is potential target to de-couple checkpoint inhibitor-induced colitis from antitumor immunity. J Clin Oncol 37(Supplement 15):2616-2616, 2019. e-Pub 2019.
      25. Ludford K, Cohen R, Foo WC, Thomas JV, Parc Y, Svrcek M, Kopetz S, Andre T, Overman MJ. Evaluation of complete pathological remission rates in surgically resected MSI-high metastatic colorectal cancers (mCRC). J Clin Oncol 37(Supplement 15):e15046-e15046, 2019. e-Pub 2019.
      26. Jacome AA, Raghav K, Shaw KR, Fournier KF, Royal RE, Taggart MW, Foo WC, Matamoros AA, Ahmed SU, Guerra JL, Overman MJ, Eng C. Prognostic value of genomic alterations (GA) on overall survival in appendiceal adenocarcinoma (AA). J Clin Oncol 37(Supplement 4):554-554, 2019. e-Pub 2019.
      27. Scally CP, Robinson K, Beaty K, Rafeeq S, Raghav K, Eng C, Overman M, Foo WC, Taggart MW, Mansfield P, Royal R, Fournier K. Prognostic significance of acellular mucin in patients undergoing cytoreductive surgery and HIPEC (CRS/HIPEC) for appendiceal neoplasm. Ann Surg Oncol 26:S49-S49, 2019. e-Pub 2019.
      28. Lopez A, Chen H, Harada K, Bhutani MS, Weston B, Lee JH, Maru DM, Foo WC, Rogers JE, Thomas I, Amlashi FG, Blum-Murphy MA, Rice DC, Hofstetter WL, Nguyen Q, Ajani JA. Taxane-based or platinum-based combination chemotherapy given concurrently with radiation followed by surgery resulting in high cure rates in esophageal cancer patients. J Clin Oncol 36(Supplement 15):e16051-e16051, 2018. e-Pub 2018.
      29. Solis LM, Foo WC, Parra E, Mino B, Abdel-Wahab R, Wistuba I, Kwong L, Javle M, Shroff R. Tumor-associated inflammatory cells and immune-checkpoints markers correlates with clinicopathological characteristics in intrahepatic cholangiocarcinoma (ICC). Lab Invest 98(Supplement 1):649-650, 2018. e-Pub 2018.
      30. Patel V, Samdani R, Abraham S, Estrella J, Taggart MW, Tan D, Wang H, Rashid A, Foo WC, Maru D. Clinicopathologic predictors of long-term responders to trastuzumab-based therapy in stage IV esophageal adenocarcinoma. Lab Invest 98(Supplement 1):294-295, 2018. e-Pub 2018.
      31. Kazemimood R, Foo WC, Abraham S, Rashid A, Taggart MW. Updated American Joint Commission on Cancer staging for ileal neuroendocrine tumors predicts recurrence-free interval. Lab Invest 98(Supplement 1):274, 2018. e-Pub 2018.
      32. Raghav K, Fournier KF, Johnson B, Taggart MW, Foo WC, Matamoros A, Mehdizadeh A, Ahmed SU, Guerra JL, Mansfield PF, Royal RE, Eng C, Overman MJ. Interplay of grade and stage on survival outcomes in appendiceal adenocarcinoma: corroboration of the AJCC cancer staging classification. J Clin Oncol 36(4):773, 2018. e-Pub 2018.
      33. Pestana R, Solis LM, Wang X, Abdel-Wahab R, Chen HC, Foo WC, Kwong L, Javle M, Wistuba I, Scrhoff RT. Immunoprofiling in intrahepatic cholangiocarcinoma (IHCC). J Clin Oncol 36(Supplemental), 2018. e-Pub 2018.
      34. Raghav K, Fournier KF, Johnson B, Taggart MW, Foo WC, Matamoros A, Mehdizadeh A, Ahmed S, Guerra JL, Mansfield PF, Royal RE, Overman MJ, Eng C. Comprehensive genomic profiling of appendiceal adenocarcinoma. J Clin Oncol 36(Supplemental):298-298, 2018. e-Pub 2018.
      35. Marcus R, Foo WC, Maitra A, Gupta S. Functional role of a novel epigenetic regulator in intrahepatic cholangiocarcinoma. J Am Coll Surg 225(4):S192, 2017. e-Pub 2017.
      36. Zhang HC, Dedania, BK, Foo WC, Miller E. Adverse Hepatobiliary Effects of Pegaspargase: Diagnostic Features and Potential Treatment. Am J Gastroenterol 112:S1179-S1180, 2017. e-Pub 2017.
      37. Marcus R, Foo WC, Maitra A, and Gupta S. Development of a novel mouse model for intrahepatic cholangiocarcinoma. Cancer Res 77(13 Supplement):1392, 2017. e-Pub 2017.
      38. Gunter JR, Chadha AS, Yang P, Munsell MF, Das P, Delclos ME, Foo WC, Kaur H, Clemons M, Mathew GG, Chang GJ, Rodriguez-Bigas MA, Skibber JM, Bhutani M, Raju GS, Eng C, Guha S, Krishnan S. A phase 2 randomized double blinded study evaluating the efficacy of curcumin with pre-operative chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys 98(2):E7, 2017. e-Pub 2017.
      39. Marcus R, Foo WC, Maitra A, Gupta S. Development of a novel animal model for intrahepatic cholangiocarcinoma. HPB (Oxford) 19:S72, 2017. e-Pub 2017.
      40. Hui L, Rashid A, Foo WC, Katz MH, Fleming JB, Tamm EP, and Wang H. Significance of T1a and T1b carcinoma arising in mucinous cystic neoplasm of pancreas. Lab Invest 97:445A, 2017. e-Pub 2017.
      41. Chatterjee D, Katz MH, Foo WC, Sundar M, Wang H, Varadhachary GR, Wolff RA, Lee JE, Maitra A, Fleming JB, Rashid A, and Wang H. Prognostic significance of new AJCC tumor (T) stage in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant therapies. Lab Invest 97:442A, 2017. e-Pub 2017.
      42. Foo WC, Overman M, Vilar-Sanchez E, Abraham S, Taggart A, MW. High level microsatellite instability in appendiceal carcinomas. Lab Invest 97:172A, 2017. e-Pub 2017.
      43. Marcus RK, Foo WC, Evans D, Maitra A, Gupta A. Development of a Novel Model for Intrahepatic Cholangiocarcinoma. Ann Surg Oncol 24:S104-S104, 2017. e-Pub 2017.
      44. Roberts LR, Farshidfar F, Zheng S, Gingras M, Newton Y, Shih J, Robertson AG, Hinoue T, Hoadley KA, Gibbs R, Roszik J, Covington K, Wu C, Shinbrot E, Stransky N, Hegde AM, Yang JD, Reznik E, Sadeghi S, Pedamallu CS, Ojesina AI, Hess J, Auman JT, Rhie SK, Bowlby R, Borad MJ, Stuart J, Sander C, Akbani R, Cherniack AD, Laird PW, Deshpande V, Mounajjed T, Foo WC, Torbenson M, Kleiner DE, Wheeler DA, Mcree AJ, Bathe OF, Andersen JB, Bardeesy N, Kwong LN. Integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles. Hepatology 64:227A, 2016. e-Pub 2016.
      45. Ronquillo Jr N, Rafeeq S, Fournier K, Mansfield P, Taggart MW, Foo WC. Completion resections of low grade appendiceal mucinous neoplasm with extra-appendiceal mucin and appendiceal margin involvement. Lab Invest 96:196A, 2016. e-Pub 2016.
      46. Friedman F, Foo WC, Abraham S, Rashid A, Taggart, MW. Appendiceal goblet cell carcinoid tumors-findings after definitive resection. Lab Invest 96:172A, 2016. e-Pub 2016.
      47. Agarwal A, Correa AM, Wang H, Maru D, Tan D, Abraham S, Taggart MW, Estrella JS, Foo WC, Hofstetter WL, Rashid A. Prospectively reported histologic tumor viability score and factors predicting long term survival in patients treated with trimodality therapy for primary esophageal adenocarcinoma. Lab Invest 96:159A, 2016. e-Pub 2016.
      48. Jedrzkiewicz J, Foo WC, Mansfield P, Overman M, Rafeeq S, Rashid A, Taggart MW. Conventional colonic-type adenocarcinoma of the appendix: clinicopathologic comparison with cecal adenocarcinomas. Lab Invest 96:176A, 2016. e-Pub 2016.
      49. Taggart MW, Foo WC, Abraham SC. Duplication of molecular testing at a tertiary care oncology center. Lab Invest 93:486A-487A, 2013. e-Pub 2013.
      50. Foo WC, Taggart MW, Abraham SC. Muscularis mucosae duplication and musculo-fibrous anomalies in squamous dysplasia of the esophagus. International Academy of Pathology 61(Supplement S1):79, 2012. e-Pub 2012.
      51. Krishna SG, Fleming JB, Ross WA, Bhutani MS, Krishna K, Foo WC, Gong Y, Weston BR, Raju GS, Lee JH. Non-ampullary duodenal carcinoids: role of endosonography (EUS) and outcome of endoscopic mucosal resection. Digestive Disease Week. Gastrointest Endosc 75(4):AB266, 2012. e-Pub 2012.
      52. Krishna SG, Ross WA, Fleming JB, Bhutani MS, Foo WC, Raju GS, Weston BR, Dang SM, Lee JH. Large non-ampullary duodenal adenomas (>= 1 cm): is EUS necessary before endoscopic mucosal resection (EMR). Gastrointest Endosc 75(4):AB262-AB263, 2012. e-Pub 2012.
      53. Foo WC, Rashid A, Wang H, Hamilton S, Katz MH, Lee JE, Gomez HF, Abbruzzese JL, Fleming JB, Wang H. Loss of PTEN expression in pancreatic ductal adenocarcinoma is associated with poor survival. Lab Invest 92:442A-443A, 2012. e-Pub 2012.
      54. Zhao Q, Weng S, Foo WC, Estrella JS, Yao JC, Wang H, Wang H, Rashid A. Loss of expression of DAXX and ATRX in low-grade neuroendocrine tumors (carcinoid tumors). Lab Invest 92:187A, 2012. e-Pub 2012.
      55. Krishna SG, Dang SM, Foo WC, Ross WA, Lee JH. Pancreatic involvement in multiple myeloma: clinical and diagnostic features for the gastroenterologist. Digestive Disease Week, 2012. e-Pub 2012.
      56. Foo WC, Colombo C, Whitting D, Hajibashi S, Wang WL, Lev D, Lazar A. FAP-assodated desmoid fibromatosis: a comparison to their sporadic counterparts. Lab Invest 91:13A-14A, 2011. e-Pub 2011.
      57. Foo WC, Wick MR, Hornick JL. Immunohistochemical staining for TLE1 distinguishes synovial sarcoma from histologic mimics. Lab Invest 90:20A, 2010. e-Pub 2010.
      58. Liang, CW, Rossi S, Dei Toss AP, Hornick JL, Foo WC, Fletcher JA. MicroGIST genomic aberrations highlight early mechanisms in GIST pathogenesis. Lab Invest 90:23A, 2010. e-Pub 2010.
      59. Foo WC, Carlson JW, Lyon E, Walton D, Farmer P, Nose V. Partners In pathology: a model for department-wide educational experience. Lab Invest 89:113A, 2009. e-Pub 2009.
      60. Hofer MD, Foo WC, Gordon G, Sugarbaker DJ, Bueno R, Corson JM, Chirieac LR. The extent of sarcomatoid component is an independent predictor of survival in malignant mesothelioma. Histopathology 53(Supplement 1):360, 2008. e-Pub 2008.
      61. Foo WC, Hofer MD, Sugarbaker DJ, Corson JM, Chirieac LR. The accuracy of pretreatment biopsy of pleural malignant mesothelioma in predicting histopathologic type in extrapleural pneumonectomy. Lab Invest 88:341A-342A, 2008. e-Pub 2008.
      62. Carlson JW, Lyon E, Walton D, Foo WC, Sievers AC, Shulman LN, Farmer P, Nose V. Partners in pathology: a collaborative model to bring pathology to resource poor settings. Lab Invest 88:284A-285A, 2008. e-Pub 2008.

      Book Chapters

      1. Oppliger, F, Foo, WC, Chun, YS. Multigene Testing for Prognostication and Therapeutic Actionability. In: Colorectal Liver Metastasis, 467-473, 2022.
      2. Foo WC. Esophagus. In: Grossing, Staging, and Reporting. An Integrated Model of Modern Surgical Pathology. College of American Pathologists, 2021.
      3. Foo WC. Distal Extrahepatic Bile Duct. In: Grossing, Staging, and Reporting. An Integrated Model of Modern Surgical Pathology. College of American Pathologists, 2021.
      4. Foo WC. Perihilar Bile Duct. In: Grossing, Staging, and Reporting. An Integrated Model of Modern Surgical Pathology. College of American Pathologists, 2021.
      5. Foo WC. Gallbladder. In: Grossing, Staging, and Reporting. An Integrated Model of Modern Surgical Pathology. College of American Pathologists, 2021.
      6. Taggart MW, Foo WC, Lee SM. Tumors of the gastrointestinal intestinal system including the pancreas. In: Oncological Surgical Pathology. Springer Nature, 691-870, 2020.
      7. Foo WC, Wang H. Pathology and Molecular Pathology of Pancreatic Cancer. In: Pathology and Epidemiology of Cancer. Springer International Publishing, 489-509, 2017.
      8. Foo WC, Lazar A. Pathology of desmoid tumors. In: Desmoid tumors. Springer, Dordrecht, 17-28, 2012.

      Books (edited and written)

      1. Oppliger, F, Foo, WC, Chun, YS. Multigene Testing for Prognostication and Therapeutic Actionability, 2022.
      Read More
      Less

      Patient Reviews


      CV information above last modified August 31, 2026

      Request an Appointment

      Whether you are ready to make an appointment now or have questions for our expert team, we are standing by to help.
      Learn more

      Related Links

      • Care Centers and Clinics

      • Departments and Divisions

      • Labs

      Clinical Trials

      Our patients have access to clinical trials offering promising new treatments that cannot be found anywhere else.
      Learn more

      Help #EndCancer

      Give Now

      Your gift will help make a tremendous difference.
      Donate

      Donate Blood

      Our patients depend on blood and platelet donations.

      Make an appointment

      Shop UT MD Anderson

      Show your support for our mission through branded merchandise.

      View products
      Subscribe to our Cancerwise newsletter
      UT MD Anderson logoUT MD Anderson logo
      • Explore
      • Patients & Family
      • Prevention & Screening
      • Donors & Volunteers
      • For Physicians
      • Research
      • Education & Training
      • Clinical Trials
      • Languages
      • About
      • About UT MD Anderson
      • Careers
      • Blog
      • Newsroom
      • Editorial Standards
      • For Employees
      • Merchandise
      • Title IX Reporting (Sexual Misconduct)
      • Price Transparency
      • Finding Your Way
      • Our Doctors
      • Locations
      • Directions
      • Sitemap
      • DIGITAL ACCESSIBILITY
      • Accessibility Policy MD Anderson works with Level Access to ensure our website is accessible and functional for all users. Free assistive technology is provided for people with physical disabilities. To learn more or to download the assistive technology tool, visit https://www.levelaccess.com/MDAnderson
      • GET IN TOUCH
      • Call
        1-877-632-6789
      • Ask a question
      • Stay Connected
      • Cancerwise Podcast
      • More
      • Website Privacy Policy
      • Legal Statement & Policies
      • Reports to the State
      • Emergency Alert Information
      • State of Texas Links
      • Our Cancer Network
      • Vendors & Suppliers
      UT MD Anderson logo
      The mission of The University of Texas MD Anderson Cancer Center is to eliminate cancer in Texas, the nation, and the world through outstanding programs that integrate patient care, research and prevention, and through education for undergraduate and graduate students, trainees, professionals, employees and the public.

      © 2026 The University of Texas MD Anderson Cancer Center. All rights reserved.

      Top